1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

Abstract

RO is a bispecific antibody-like fusion protein based on a trimeric 4-1BB ligand and a targeting Fab moiety recognizing fibroblast activation protein-α (FAP) abundantly expressed by cancer-associated fibroblasts in many tumors. Upon TCR/CD3 engagement, simultaneous binding of FAP and 4-1BB results in clustering and activation of T- and NK- cells at the tumor site, thereby leading to potent anti-tumor activity in a panel of preclinical models.